Latest Pharmaceuticals News

Page 45 of 73
CLINUVEL Pharmaceuticals is preparing to elevate its American Depository Receipt program to a Nasdaq Level II listing by the end of 2025, aiming to enhance visibility and trading access in the U.S. without altering its primary ASX listing.
Ada Torres
Ada Torres
22 Aug 2025
LTR Pharma has announced that its erectile dysfunction treatment SPONTAN now boasts an 18-month shelf life, surpassing commercial standards and paving the way for international market growth.
Victor Sage
Victor Sage
22 Aug 2025
Healius reported a 5.7% rise in FY25 revenue with underlying EBIT meeting consensus, buoyed by strong pathology growth and a significant profit from the Lumus Imaging sale. Despite challenges at Agilex Biolabs and a major goodwill impairment, the company targets improved margins by 2027.
Ada Torres
Ada Torres
21 Aug 2025
Medical Developments International has reported a remarkable turnaround in FY25, posting a net profit after tax and securing paediatric approval for its flagship product Penthrox in Europe.
Ada Torres
Ada Torres
21 Aug 2025
Medical Developments International Ltd reported an 18% increase in revenue to $39.1 million for FY25, returning to profitability with a net profit after tax of $0.1 million. The company advanced its Penthrox market expansion through regulatory approvals and new partnerships.
Ada Torres
Ada Torres
21 Aug 2025
IDT Australia Limited reported a strong 40.6% increase in revenue to $19.86 million for FY25, driven by growth in advanced therapies and contract disbursements. However, the company’s net loss widened to $8.06 million as it transitions from its ‘Rebuild Strategy’ to a new phase focused on sustainable profitability.
Victor Sage
Victor Sage
21 Aug 2025
Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.
Ada Torres
Ada Torres
21 Aug 2025
Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial growth and strategic investments, while advancing key clinical trials and maintaining full-year guidance.
Ada Torres
Ada Torres
21 Aug 2025
Telix Pharmaceuticals reported a robust 63% increase in revenue to $390.4 million for the first half of 2025, driven by strong Illuccix sales and the acquisition of RLS Radiopharmacies. Despite this growth, the company recorded a net loss of $2.3 million, reflecting increased investments and finance costs.
Ada Torres
Ada Torres
21 Aug 2025
Invion Limited secures a pivotal FDA Orphan Drug Designation for its lead candidate INV043, targeting anal cancer with promising preclinical results and a fast-tracked development path.
Ada Torres
Ada Torres
20 Aug 2025
LTR Pharma’s intranasal ED treatment SPONTAN achieves peak effect up to five times faster than oral tablets, according to new peer-reviewed clinical data published in a leading European journal.
Ada Torres
Ada Torres
20 Aug 2025
Pharmx Technologies has reported a 13% revenue increase to $7.5 million for FY25, driven by expanded partnerships and platform innovations, despite a dip in EBITDA due to heavy investment.
Ada Torres
Ada Torres
20 Aug 2025